TR200103693T2 - Yeni formülasyon - Google Patents

Yeni formülasyon

Info

Publication number
TR200103693T2
TR200103693T2 TR2001/03693T TR200103693T TR200103693T2 TR 200103693 T2 TR200103693 T2 TR 200103693T2 TR 2001/03693 T TR2001/03693 T TR 2001/03693T TR 200103693 T TR200103693 T TR 200103693T TR 200103693 T2 TR200103693 T2 TR 200103693T2
Authority
TR
Turkey
Prior art keywords
dosage form
extract
omeprazole
new formulation
basic
Prior art date
Application number
TR2001/03693T
Other languages
English (en)
Turkish (tr)
Inventor
Johan Lundberg Per
Sj�blom Brita
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200103693T2 publication Critical patent/TR200103693T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
TR2001/03693T 1999-06-22 2000-06-20 Yeni formülasyon TR200103693T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation

Publications (1)

Publication Number Publication Date
TR200103693T2 true TR200103693T2 (tr) 2002-05-21

Family

ID=20416209

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03693T TR200103693T2 (tr) 1999-06-22 2000-06-20 Yeni formülasyon

Country Status (29)

Country Link
EP (1) EP1191926B1 (enExample)
JP (1) JP2003502359A (enExample)
KR (1) KR100717661B1 (enExample)
CN (1) CN1243547C (enExample)
AT (1) ATE291901T1 (enExample)
AU (1) AU778158B2 (enExample)
BR (1) BR0011894A (enExample)
CA (1) CA2376226C (enExample)
CZ (1) CZ20014579A3 (enExample)
DE (1) DE60019116T2 (enExample)
DK (1) DK1191926T3 (enExample)
EE (1) EE200100693A (enExample)
ES (1) ES2235912T3 (enExample)
HK (1) HK1044480B (enExample)
HU (1) HUP0201489A3 (enExample)
IL (2) IL146818A0 (enExample)
IS (1) IS6209A (enExample)
MX (1) MXPA01012636A (enExample)
NO (1) NO20016346L (enExample)
NZ (1) NZ516186A (enExample)
PL (1) PL352873A1 (enExample)
PT (1) PT1191926E (enExample)
RU (1) RU2240110C2 (enExample)
SE (1) SE9902386D0 (enExample)
SK (1) SK285326B6 (enExample)
TR (1) TR200103693T2 (enExample)
UA (1) UA73302C2 (enExample)
WO (1) WO2000078293A1 (enExample)
ZA (1) ZA200109803B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CA2517289A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005027876A1 (en) * 2003-08-28 2005-03-31 Ranbaxy Laboratories Limited Pharmaceutical compositions of benzimidazole and processes for their preparation
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006022560A1 (en) * 2004-08-23 2006-03-02 Auckland Uniservices Limited Gastric therapies and compositions therefor
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
KR20080081071A (ko) * 2005-12-28 2008-09-05 다케다 야쿠힌 고교 가부시키가이샤 방출 제어 고형 제제
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
WO2010029335A1 (en) 2008-09-09 2010-03-18 Astrazeneca Uk Limited Method for delivering a pharmaceutical composition to patient in need thereof
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
CN103648487B (zh) * 2011-05-13 2019-04-19 Eb Ip希博里塔布斯有限责任公司 药物递送系统
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
EP3089666B1 (en) 2013-12-31 2020-08-19 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2614730C1 (ru) * 2016-02-05 2017-03-28 Игорь Юрьевич Чичерин Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
WO2017145146A1 (en) * 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
JP6462625B2 (ja) * 2016-04-06 2019-01-30 ニプロ株式会社 カルシウムブロッカーを含有する錠剤
JP6426115B2 (ja) * 2016-04-06 2018-11-21 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ATE271379T1 (de) * 1996-11-06 2004-08-15 Wockhardt Europ Ltd System zur verzögerten freisetzung säurelabiler substanzen
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
PL196163B1 (pl) * 1997-12-08 2007-12-31 Altana Pharma Ag Nowa postać leku do podawania doustnego związków aktywnych nietrwałych w środowisku kwaśnym, zastosowanie jednostek związku aktywnego do wytwarzania leku do podawania doustnego oraz sposób wytwarzania nowej postaci leku do podawania doustnego
DK1105105T3 (da) * 1998-08-12 2006-07-17 Altana Pharma Ag Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler

Also Published As

Publication number Publication date
JP2003502359A (ja) 2003-01-21
RU2240110C2 (ru) 2004-11-20
CN1243547C (zh) 2006-03-01
ZA200109803B (en) 2003-02-28
DK1191926T3 (da) 2005-06-13
HK1044480B (en) 2005-08-26
CN1356893A (zh) 2002-07-03
HK1044480A1 (en) 2002-10-25
BR0011894A (pt) 2002-04-02
NO20016346D0 (no) 2001-12-21
MXPA01012636A (es) 2002-06-21
PL352873A1 (en) 2003-09-08
DE60019116T2 (de) 2006-02-09
CZ20014579A3 (cs) 2002-05-15
CA2376226A1 (en) 2000-12-28
NZ516186A (en) 2003-11-28
AU778158B2 (en) 2004-11-18
DE60019116D1 (de) 2005-05-04
EE200100693A (et) 2003-02-17
SK285326B6 (sk) 2006-11-03
KR20020012002A (ko) 2002-02-09
HUP0201489A2 (hu) 2002-11-28
EP1191926B1 (en) 2005-03-30
SE9902386D0 (sv) 1999-06-22
CA2376226C (en) 2009-10-20
SK18252001A3 (sk) 2002-09-10
KR100717661B1 (ko) 2007-05-14
IL146818A (en) 2007-10-31
UA73302C2 (en) 2005-07-15
ATE291901T1 (de) 2005-04-15
PT1191926E (pt) 2005-07-29
IL146818A0 (en) 2002-07-25
IS6209A (is) 2001-12-21
ES2235912T3 (es) 2005-07-16
HUP0201489A3 (en) 2004-05-28
NO20016346L (no) 2002-02-18
WO2000078293A1 (en) 2000-12-28
AU6034400A (en) 2001-01-09
EP1191926A1 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
TR200103693T2 (tr) Yeni formülasyon
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
SE8804629D0 (sv) New therapeutically active compounds
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
ATE218580T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
TR199802698T2 (xx) Valsartan�n kat� oral doz formlar�.
YU61502A (sh) Nukleozidni analozi karboksamidno modifikovanih bicikličnih baza
GEP20043315B (en) Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
TR200000635T2 (tr) Levosimendan'ın oral kompozisyonları.
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60019334D1 (de) Antivirale arznei
NO991731D0 (no) Lokalanestetikum for utvortes bruk
BR0115516A (pt) Composição farmacêutica, e, método para prevenir ou tratar hipertensão
DK1105105T3 (da) Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
IE894049L (en) Therapeutically active substituted benzimidazole and process¹for its preparation
DE60128100D1 (de) Analgetisches arzneimittel
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
DK1154776T3 (da) Farmaceutisk sammensætning, indeholdende desoxypeganin til behandling af alkoholisme
SE9604752D0 (sv) Formulation and use
TR199900013T2 (xx) Yeni bile�ikler.